Changyong Chen1, Huaiming Qiu2, Yuanhui Yao3, Zishu Zhang4, Cong Ma4, Yilong Ma5, Chang Zhao5, Hua Xiang3, Hui Zhao6, Chuansheng Zheng7, Bin Xiong7, Haiping Li1, Qingyun Long8, Jun Zhou8, Chao Luo9, Hongyao Hu10. 1. Department of Radiology, Xiangya Hospital Central South University, Changsha, China. 2. Department of Radiology, Wuhan General Hospita of Guangzhou Military, 627 Wuluo Road, Wuhan 430070, China. Electronic address: meiranhuaniw@163.com. 3. Department of Intervention, Hunan Provincial People's Hospital, Changsha, China. 4. Department of Radiology, The Second Xiangya Hospital of Central South University, Changsha, China. 5. Department of Interventional Therapy, Guangxi Medical University Affiliated Tumor Hospital, Nanning, China. 6. Department of Interventional Radiology,Department of Radiology, Renmin Hospital of Wuhan University, Jiefang Road 238, Wuhan 430060, China. 7. Department of Interventional Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 8. Department of Radiology, Zhongnan Hospital of Wuhan University, Wuhan, China. 9. Department of Radiology, Wuhan General Hospita of Guangzhou Military, 627 Wuluo Road, Wuhan 430070, China. 10. Department of Interventional Radiology,Department of Radiology, Renmin Hospital of Wuhan University, Jiefang Road 238, Wuhan 430060, China. Electronic address: huhongyao@vip.163.com.
Abstract
BACKGROUND: Transarterial chemoembolization (TACE) is widely applied in hepatocellular carcinoma (HCC) patients who are not suitable for surgical treatment. We aimed to investigate the treatment outcomes and comprehensive prognostic factors of CalliSpheres® microspheres (CSM) drug-eluting bead TACE (DEB-TACE) treatment and conventional TACE (cTACE) treatment in HCC patients. METHODS: Three hundred and thirty-five HCC patients received DEB-TACE or cTACE treatment were consecutively enrolled in multi-center, retrospective cohort study. Treatment response was conducted at M1, M3 or M6 after treatment. Progression free survival (PFS) and overall survival (OS) were recorded. Thirty-seven baseline factors including demographic characteristics, clinical features, biochemical indexes and previous treatment histories were selected. RESULTS: In total patients, history of drink and largest nodule size≥7cm independently predicted worse ORR, DEB-TACE predicted better OS, while largest nodule size≥7cm, increased Child-Pugh stage, ALB abnormal, ALP abnormal or AFP abnormal predicted worse survival. For DEB-TACE group, previous cTACE and ANC abnormal independently predicted worse ORR, and hepatic vein invasion, increased Child-Pugh stage or AFP abnormal independently predicted poor survival. For cTACE group, largest nodule size≥7cm independently predicted poor ORR, and multifocal disease as well as ALB abnormal predicted poor OS. CONCLUSIONS: History of drink, largest nodule size≥7cm, DEB-TACE, increased Child-Pugh stage, abnormal ALB, ALP or AFP are potential prognostic factors in total patients, previous cTACE and ANC abnormal, hepatic vein invasion, increased Child-Pugh stage or AFP abnormal are potential prognostic factors in DEB-TA group, and largest nodule size≥7cm, multifocal disease and ALB abnormal are potential prognostic factors in cTACE group.
BACKGROUND: Transarterial chemoembolization (TACE) is widely applied in hepatocellular carcinoma (HCC) patients who are not suitable for surgical treatment. We aimed to investigate the treatment outcomes and comprehensive prognostic factors of CalliSpheres® microspheres (CSM) drug-eluting bead TACE (DEB-TACE) treatment and conventional TACE (cTACE) treatment in HCC patients. METHODS: Three hundred and thirty-five HCC patients received DEB-TACE or cTACE treatment were consecutively enrolled in multi-center, retrospective cohort study. Treatment response was conducted at M1, M3 or M6 after treatment. Progression free survival (PFS) and overall survival (OS) were recorded. Thirty-seven baseline factors including demographic characteristics, clinical features, biochemical indexes and previous treatment histories were selected. RESULTS: In total patients, history of drink and largest nodule size≥7cm independently predicted worse ORR, DEB-TACE predicted better OS, while largest nodule size≥7cm, increased Child-Pugh stage, ALB abnormal, ALP abnormal or AFP abnormal predicted worse survival. For DEB-TACE group, previous cTACE and ANC abnormal independently predicted worse ORR, and hepatic vein invasion, increased Child-Pugh stage or AFP abnormal independently predicted poor survival. For cTACE group, largest nodule size≥7cm independently predicted poor ORR, and multifocal disease as well as ALB abnormal predicted poor OS. CONCLUSIONS: History of drink, largest nodule size≥7cm, DEB-TACE, increased Child-Pugh stage, abnormal ALB, ALP or AFP are potential prognostic factors in total patients, previous cTACE and ANC abnormal, hepatic vein invasion, increased Child-Pugh stage or AFP abnormal are potential prognostic factors in DEB-TA group, and largest nodule size≥7cm, multifocal disease and ALB abnormal are potential prognostic factors in cTACE group.